A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
Clinical trial NCT06153238 · COMPLETED
Trial details
- NCT number
- NCT06153238
- Sponsor
- Sandoz
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-15
- Primary completion
- 2026-05-05
- Enrollment
- 322
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.